The purpose of the GLYDER clinical study is to evaluate the safety and effectiveness of the GLYDER device in patients with a history of facet pain demonstrated by treatment history and diagnosis as a baseline. This is a prospective, multi-center clinical evaluation.
Professor Hans Jorg Meisel, M.D. Ph.D., Director, Center of Neurosciences/Chair, Department of Neurosurgery, BG-Clinic Bergmannstrost, Halle, Germany is the principal investigator for the study. "The GLYDER device was very easy to implant into the facet joints. Preoperatively, both of these patients had long lasting facet joint syndrome. The first postoperative examinations showed a good result concerning the patients' lumbar pain giving us the impression of a favorable outcome from the GLYDER surgery. We look forward to continuing the study and reporting the final results," said Professor Meisel.
Luiz Pimenta, M.D., Ph.D., Medical Director, Instituto de Patologia da Coluna, Sao Paulo, Brazil, who implanted the first-in-man GLYDER devices said, "Early results suggest that GLYDER could be a good option for treating patients suffering from facet pain. More study of this device is needed so we are looking forward to seeing the results from the European study."
Facetogenic pain has been shown to be the source of pain for up to 30% of patients suffering from low back pain. Patients who suffer from this condition typically receive therapeutic facet injections which temporarily address the problem but require long-term repeat treatments.
About Zyga Technology, Inc.
Zyga Technology, Inc. based in Minneapolis, MN, was founded to develop and market innovative, minimally invasive surgical solutions to treat conditions of the spine. Each year millions of people in the U.S. suffer from symptoms of back pain. Patients and physicians alike are demanding the latest innovations to treat back pain. Zyga Technology is responding to those challenges by delivering products and procedures that use the latest minimally invasive surgical techniques.